Clinical trial

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

NCT00335374

Study summary

ClinicalTrials.gov

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Pardoprunox Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2007-08-01

PhasePHASE3

Conditions

Early Stage Parkinson's Diseaseunresolved

Interventions

PardoprunoxDRUG

Sponsors & collaborators

Solvay Pharmaceuticalslead sponsor

Mapped research locations

BostonMassachusetts, United States2 RomaItaly2 BangkokThailand2 GroningenNetherlands2 Cape TownSouth Africa2 VilniusLithuania2 OstravaCzechia2 MumbaiIndia2 BirminghamAlabama, United States1 MinneapolisMinnesota, United States1 TaipeiTaiwan1 New HavenConnecticut, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00335374 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.